Journal
JOURNAL OF CLINICAL LIPIDOLOGY
Volume 10, Issue 4, Pages 808-815Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2016.03.001
Keywords
Apolipoprotein A-II; Oxidations; Mass spectrometry; Diabetes
Categories
Funding
- National Institute of Heart, Lung and Blood [K23HL107389]
- American Heart Association [15BGIA25690024]
- USC CTSI [UL1TR000130]
- National Institute of Diabetes And Digestive and Kidney Diseases [R01DK082542, R24DK090958]
Ask authors/readers for more resources
BACKGROUND: Apolipoprotein A-II (apoA-11) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. OBJECTIVE: Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. METHODS: Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. RESULTS: Six apoA-11 proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-11 were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. CONCLUSION: The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes. (C) 2016 National Lipid Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available